Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 23

1.

ALIAS (Albumin in Acute Ischemic Stroke) Trials: Analysis of the Combined Data From Parts 1 and 2.

Martin RH, Yeatts SD, Hill MD, Moy CS, Ginsberg MD, Palesch YY; ALIAS Parts 1 and 2 and NETT Investigators.

Stroke. 2016 Sep;47(9):2355-9. doi: 10.1161/STROKEAHA.116.012825. Epub 2016 Jul 26.

2.

Albumin Administration in Acute Ischemic Stroke: Safety Analysis of the ALIAS Part 2 Multicenter Trial.

Hill MD, Martin RH, Palesch YY, Moy CS, Tamariz D, Ryckborst KJ, Jones EB, Weisman D, Pettigrew C, Ginsberg MD.

PLoS One. 2015 Sep 1;10(9):e0131390. doi: 10.1371/journal.pone.0131390. eCollection 2015.

3.

Symptomatic intracranial hemorrhage in the ALIAS Multicenter Trial: relationship to endovascular thrombolytic therapy.

Ginsberg MD, Hill MD.

Int J Stroke. 2015 Jun;10(4):494-500. doi: 10.1111/ijs.12476. Epub 2015 Mar 22.

4.

High-dose albumin treatment for acute ischaemic stroke (ALIAS) Part 2: a randomised, double-blind, phase 3, placebo-controlled trial.

Ginsberg MD, Palesch YY, Hill MD, Martin RH, Moy CS, Barsan WG, Waldman BD, Tamariz D, Ryckborst KJ; ALIAS and Neurological Emergencies Treatment Trials (NETT) Investigators.

Lancet Neurol. 2013 Nov;12(11):1049-58. doi: 10.1016/S1474-4422(13)70223-0. Epub 2013 Sep 27.

5.

Predictors of outcome in patients with spinal cord ischemia after open aortic repair.

Becker DA, McGarvey ML, Rojvirat C, Bavaria JE, Messé SR.

Neurocrit Care. 2013 Feb;18(1):70-4. doi: 10.1007/s12028-012-9807-9.

PMID:
23233328
6.

Visualizing the cortical microcirculation in patients with stroke.

Ginsberg MD.

Crit Care Med. 2011 May;39(5):1228-30. doi: 10.1097/CCM.0b013e318211fa5d. No abstract available.

7.

The Albumin in Acute Stroke Part 1 Trial: an exploratory efficacy analysis.

Hill MD, Martin RH, Palesch YY, Tamariz D, Waldman BD, Ryckborst KJ, Moy CS, Barsan WG, Ginsberg MD; ALIAS Investigators; Neurological Emergencies Treatment Trials Network.

Stroke. 2011 Jun;42(6):1621-5. doi: 10.1161/STROKEAHA.110.610980. Epub 2011 May 5.

8.

The albumin in acute stroke (ALIAS) multicenter clinical trial: safety analysis of part 1 and rationale and design of part 2.

Ginsberg MD, Palesch YY, Martin RH, Hill MD, Moy CS, Waldman BD, Yeatts SD, Tamariz D, Ryckborst K; ALIAS Investigators.

Stroke. 2011 Jan;42(1):119-27. doi: 10.1161/STROKEAHA.110.596072. Epub 2010 Dec 16.

9.

Teaching NeuroImages: occlusion of all 4 major extracranial vessels.

Mullen MT, Pantelyat A, Pukenas BA, Messé SR.

Neurology. 2010 Sep 21;75(12):e51. doi: 10.1212/WNL.0b013e3181f39aca. No abstract available.

10.

A web-based medical safety reporting system for a large multicenter clinical trial: the ALIAS experience.

Zhao W, Waldman BD, Dillon C, Pauls K, Kim J, Patterson L, Ginsberg MD, Hill MD, Palesch Y.

Contemp Clin Trials. 2010 Nov;31(6):536-43. doi: 10.1016/j.cct.2010.08.010. Epub 2010 Sep 7.

11.

Insulin resistance, type 2 diabetes, and AD: cerebrovascular disease or neurodegeneration?

Luchsinger JA.

Neurology. 2010 Aug 31;75(9):758-9. doi: 10.1212/WNL.0b013e3181eee287. Epub 2010 Aug 25. No abstract available.

PMID:
20739648
12.

Step-forward randomization in multicenter emergency treatment clinical trials.

Zhao W, Ciolino J, Palesch Y.

Acad Emerg Med. 2010 Jun;17(6):659-65. doi: 10.1111/j.1553-2712.2010.00746.x.

13.

Less could be more when it comes to diffusion imaging of acute stroke.

Kosior RK, Hill MD, Frayne R.

Neurology. 2010 Jun 15;74(24):1936-7. doi: 10.1212/WNL.0b013e3181e59d95. Epub 2010 May 19. No abstract available.

PMID:
20484683
14.

Current status of neuroprotection for cerebral ischemia: synoptic overview.

Ginsberg MD.

Stroke. 2009 Mar;40(3 Suppl):S111-4. doi: 10.1161/STROKEAHA.108.528877. Epub 2008 Dec 8. Review.

15.

The albumin in acute stroke trial (ALIAS); design and methodology.

Hill MD, Moy CS, Palesch YY, Martin R, Dillon CR, Waldman BD, Patterson L, Mendez IM, Ryckborst KJ, Tamariz D, Ginsberg MD; ALIAS Investigators.

Int J Stroke. 2007 Aug;2(3):214-9. doi: 10.1111/j.1747-4949.2007.00143.x.

PMID:
18705947
16.

Neuroprotection for ischemic stroke: past, present and future.

Ginsberg MD.

Neuropharmacology. 2008 Sep;55(3):363-89. doi: 10.1016/j.neuropharm.2007.12.007. Epub 2008 Mar 4. Review.

17.

Experimental intracerebral hematoma in the rat: characterization by sequential magnetic resonance imaging, behavior, and histopathology. Effect of albumin therapy.

Belayev L, Obenaus A, Zhao W, Saul I, Busto R, Wu C, Vigdorchik A, Lin B, Ginsberg MD.

Brain Res. 2007 Jul 9;1157:146-55. Epub 2007 May 8.

PMID:
17543290
18.

Life after cerovive: a personal perspective on ischemic neuroprotection in the post-NXY-059 era.

Ginsberg MD.

Stroke. 2007 Jun;38(6):1967-72. Epub 2007 May 3. Review.

PMID:
17478741
19.

The ALIAS (ALbumin In Acute Stroke) Phase III randomized multicentre clinical trial: design and progress report.

Ginsberg MD, Palesch YY, Hill MD.

Biochem Soc Trans. 2006 Dec;34(Pt 6):1323-6.

PMID:
17073812
20.

The ALIAS Pilot Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke--I: Physiological responses and safety results.

Ginsberg MD, Hill MD, Palesch YY, Ryckborst KJ, Tamariz D.

Stroke. 2006 Aug;37(8):2100-6. Epub 2006 Jun 29.

PMID:
16809571

Supplemental Content

Loading ...
Support Center